Home Cart Sign in  
Chemical Structure| 304462-19-9 Chemical Structure| 304462-19-9

Structure of AVE 0991
CAS No.: 304462-19-9

Chemical Structure| 304462-19-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AVE 0991 is a nonpeptide Ang-(1-7) receptor Mas agonist.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AVE 0991

CAS No. :304462-19-9
Formula : C29H32N4O5S2
M.W : 580.72
SMILES Code : CCNC(NS(=O)(C1=C(C=C(S1)CC(C)C)C2=CC=C(C=C2)CN3C(C=O)=C(N=C3C4=CC=CC=C4)OC)=O)=O
MDL No. :MFCD27992063
InChI Key :QTOZBSNPDCWHPV-UHFFFAOYSA-N
Pubchem ID :9851724

Safety of AVE 0991

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of AVE 0991

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary astrocytes 0.01μM, 0.1μM, 1μM 24 h To investigate the effects of AVE 0991 on Aβ-induced inflammation and autophagy in astrocytes. Results showed that AVE 0991 significantly inhibited the release of inflammatory cytokines (IL-1β, IL-6, TNF-α) and promoted autophagy by upregulating LC3 and Beclin-1 expression and downregulating P62 levels. J Inflamm Res. 2023 Feb 1;16:391-406.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CD2F1 mice Cancer cachexia model Oral gavage 1 mg/kg and 15 mg/kg Low dose: 10 administrations over 13 days; High dose: 9 administrations over 10 days To evaluate the effects of AVE 0991 on tumor growth and muscle wasting in mice with cancer cachexia, results showed that AVE 0991 slowed tumor development, reduced weight loss, improved locomotor activity, and attenuated muscle wasting. Cancer Res. 2019 Feb 15;79(4):706-719
Rats Subarachnoid hemorrhage model Intranasal administration 0.9 mg/kg Single dose, observed up to 28 days To evaluate the protective effects of AVE 0991 on oxidative stress and neuronal apoptosis after subarachnoid hemorrhage. Results showed that AVE 0991 significantly improved neurobehavioral scores and reduced oxidative stress and neuronal apoptosis through the Mas/PKA/CREB/UCP-2 pathway. Redox Biol. 2019 Jan;20:75-86
APP/PS1 transgenic mice Alzheimer's disease model Intraperitoneal injection 1, 3, 10 mg/kg Once daily for 30 consecutive days To evaluate the effects of AVE 0991 on cognitive function, neuronal damage, and inflammation in APP/PS1 mice. Results showed that AVE 0991 (3 and 10 mg/kg) significantly improved cognitive function, reduced neuronal death and synaptic damage, and suppressed astrocyte-mediated inflammation. J Inflamm Res. 2023 Feb 1;16:391-406.
Aged male Sprague-Dawley rats Laparotomy-induced delayed neurocognitive recovery model Intranasal administration 0.9 mg/kg Single dose AVE 0991 significantly improved hippocampus-dependent learning and memory deficits induced by surgery, attenuated hippocampal neuroinflammation by reducing microglial activation marker CD11b and inflammatory molecules, and restored BBB integrity by modulating MMP-9/TIMP-3 balance and occludin expression. Front Aging Neurosci. 2021 Feb 15;13:624387
Rats Congestive heart failure model Intraperitoneal injection 24 µg/kg/h Continuous for 28 days To evaluate the chronic effects of AVE 0991 on renal function and cardiac hypertrophy in rats with congestive heart failure. Results showed that chronic administration of AVE 0991 exerted significant diuretic, natriuretic, and kaliuretic effects in CHF rats, reduced serum creatinine and aldosterone levels, and attenuated cardiac hypertrophy. Int J Mol Sci. 2023 Jul 14;24(14):11470

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.72mL

0.34mL

0.17mL

8.61mL

1.72mL

0.86mL

17.22mL

3.44mL

1.72mL

References

 

Historical Records

Categories